A research project currently being undertaken by leading professionals in the field of hearing health, including our own NextSense team members, is the Cochlear Implant Neurotrophin Gene Therapy Trial.
This trial evaluates the safety and efficacy of neurotrophin gene therapy delivered during cochlear implant surgery.
The Cochlear Implant Neurotrophin Gene Therapy Trial (CINGT) comes from extensive studies in animals that showed improvement in performance of cochlear implants when auditory nerve fibres were re-grown towards the implant electrode array.
This is done by delivering small molecules (neurotrophic factors) that enhance the growth and survival potential of neurons to targeted cells in the hearing organ (the cochlea).
Interested in being part of the trial?
Contact us todayResearch Team
-
Clinical Professor Catherine Birman OAM
MBBS, PhD, FRACS, GAICDClinical Professor Birman is one of the most experienced cochlear implant surgeons in the world, having performed more than 1500 cochlear implant procedures for children and adults from three months to well over 90 years.
-
The Australian Childhood Vision Impairment Register (ACVIR)
The Australian Childhood Vision Impairment Register is sponsored by NextSense with support from Guide Dogs, Vision Australia, low vision service providers and families of children with vision loss.
-
Infant Monitor of Vocal Production (IMP)
The Infant Monitor of Vocal Production (IMP) enables parents and professionals to conjointly review and assess an infant's vocal progress toward speech.
-
Paediatric hearing assessment with tele-audiology
With the improvement of technology, telemedicine has emerged as a means to provide improved access for children in remote locations.
